References
Patrick K, Wade R, Goulden N, Mitchell C, Moorman AV, Rowntree C, Jenkinson S, Hough R, Vora A (2014) Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 166:421–424
Wood BL, Winter SS, Dunsmore KP, Devidas M, Chen S, Asselin B et al (2014) T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children’s Oncology Group (COG) study AALL0434. Blood 124(21):1
Jain N, Lamb AV, O’Brien S, Ravandi F, Konopleva M, Jabbour E et al (2016) Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood 127:1863–1869
Vadillo E, Dorantes-Acosta E, Pelayo R, Schnoor M (2018) T cell acute lymphoblastic leukemia (T-ALL): new insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Rev 32:36–51
Zhou Y, Fan X, Routbort M, Cameron Yin C, Singh R, Bueso-Ramos C, Thomas DA, Milton DR, Medeiros LJ, Lin P (2013) Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma. Mod Pathol 26:1338–1345
Wilson FP, Berns JS (2014) Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis 21:18–26
Riccio B, Mato A, Olson EM, Berns JS, Luger S (2006) Spontaneous tumor lysis syndrome in acute myeloid leukemia: two cases and a review of the literature. Cancer Biol Ther 5:1614–1617
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Shinya Kimura has received research grants from Chugai Pharmaceutical, Daiichi-Sankyo, Astellas, TAIHO PHARMA, Novartis, Takeda, Asahi Kasei Pharma, Nissan Chemical, and Ohara. Shinya Kimura has received a speaker honorarium from Bristol-Myers Squibb, Novartis, Pfizer, and Otsuka Pharmaceutical.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from the patient’s parents.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kidoguchi, K., Yokoo, M., Umino, A. et al. Terminal deoxynucleotidyl transferase (TdT) negative early T cell precursor acute lymphoblastic leukemia (ETP-ALL) with spontaneous acute kidney injury. Ann Hematol 99, 885–886 (2020). https://doi.org/10.1007/s00277-020-03943-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-020-03943-5